SAN DIEGO, Aug. 10, 2007 (PRIME NEWSWIRE) -- Pacific Beach BioSciences, Inc. (PB BioSciences), a development stage biopharmaceutical company that develops novel therapeutics for the treatment and prevention of infectious diseases, and Dong Wha Pharmaceutical Ind. Co., a Seoul, Korea-based, pharmaceutical company (Dong Wha), today announced an agreement granting PB BioSciences exclusive rights to develop and commercialize Zabofloxacin (PB-101, DW-224a). PB BioSciences plans to develop Zabofloxacin for the treatment of various respiratory tract infections. PB BioSciences was founded by Paramount BioSciences, LLC.
